CompletedNot Applicable

The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography

Israel100 participantsStarted 2010-03

Plain-language summary

The aim of the current study is to evaluate prospectively whether concomitant administration of RAAS blockers (namely ACE-I and ARBs') influence the change in estimated GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1\. Age\>18 years * 2\. Subjects on chronic therapy with ACE-I and/or ARBs' (confirmed by electronic records in their medical file) * 3\. Subjects planned to undergo non-emergent coronary angiography. * 4\. Signed informed consent Exclusion Criteria: * 1\. eGFR\<30 ml/min at baseline * 2\. Chronic utilization of NSAIDS and Cox-2 selective inhibitors * 3\. Chronic treatment with mineralocorticosteroid receptor blocker * 4\. Systolic blood pressure\<90 mmHg * 5\. Planned staged (repeated) procedure within 48 hours * 6\. Administration of contrast within 14 days prior to the enrollment * 7\. contraindication to stop ACE-I or ARB'S

What they're measuring

Change in eGFR from baseline to 48 hours following the exposure to the contrast.

Timeframe: 48 hours after exposure to the contrast

Trial details

NCT IDNCT01071642

SponsorSoroka University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-09

View on ClinicalTrials.gov More Blood Pressure trials